With regard to the baseline frequency of BM in pts with ALK+ NSCLC at the time of diagnosis of the disease, two retrospective studies showed a frequency of approximately 25 %, which is comparable to that observed in other subsets of NSCLC driven by EGFR and Kirsten rat sarcoma viral oncogene homolog (KRAS) [14, 15]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.